You are here

J Med Chem DOI:10.1021/acs.jmedchem.1c00507

Discovery of a First-in-Class Inhibitor of the PRMT5-Substrate Adaptor Interaction.

Publication TypeJournal Article
Year of Publication2021
AuthorsMcKinney, DC, McMillan, BJ, Ranaghan, MJ, Moroco, JA, Brousseau, M, Mullin-Bernstein, Z, O'Keefe, M, McCarren, P, Mesleh, MF, Mulvaney, KM, Robinson, F, Singh, R, Bajrami, B, Wagner, FF, Hilgraf, R, Drysdale, MJ, Campbell, AJ, Skepner, A, Timm, DE, Porter, D, Kaushik, VK, Sellers, WR, Ianari, A
JournalJ Med Chem
Date Published2021 Aug 03
ISSN1520-4804
Abstract

PRMT5 and its substrate adaptor proteins (SAPs), pICln and Riok1, are synthetic lethal dependencies in MTAP-deleted cancer cells. SAPs share a conserved PRMT5 binding motif (PBM) which mediates binding to a surface of PRMT5 distal to the catalytic site. This interaction is required for methylation of several PRMT5 substrates, including histone and spliceosome complexes. We screened for small molecule inhibitors of the PRMT5-PBM interaction and validated a compound series which binds to the PRMT5-PBM interface and directly inhibits binding of SAPs. Mode of action studies revealed the formation of a covalent bond between a halogenated pyridazinone group and cysteine 278 of PRMT5. Optimization of the starting hit produced a lead compound, BRD0639, which engages the target in cells, disrupts PRMT5-RIOK1 complexes, and reduces substrate methylation. BRD0639 is a first-in-class PBM-competitive inhibitor that can support studies of PBM-dependent PRMT5 activities and the development of novel PRMT5 inhibitors that selectively target these functions.

DOI10.1021/acs.jmedchem.1c00507
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/34342224?dopt=Abstract

Alternate JournalJ Med Chem
PubMed ID34342224